Created in 1963 by Alain Mérieux, bioMérieux is 59% owned by Mérieux Alliance
and is listed on NYSE Euronext Paris.
Its mission is to improve world health by developing innovative in vitro diagnostic solutions. Its tools are key in the healthcare chain. They empower clinicians with information to determine their patients' diagnosis, prognosis and to monitor their treatment, constantly improving the quality and the personalization of patient care. In industry, they play a crucial role in the prevention of sanitary risks by ensuring consumer safety.
bioMérieux develops diagnostic solutions for medical and industrial applications:
In these two areas of application, bioMérieux develops products and markets diagnostic systems composed of:
To the above ends it combines traditional technologies with the latest advances in fields such
as molecular biology and nanotechnology.
bioMérieux pursues an ambitious policy of innovation with an annual investment of more than 11% of its sales in R&D, the highest percentage among major in vitro diagnostics companies. It is building partnerships with the international scientific community and actively participates in the Lyonbiopôle international competitiveness cluster in biology, of which it is a founding member.
A world player in in vitro diagnosis for over 50 years, bioMérieux is present in more than 150 countries through 41 subsidiaries and a large network of distributors. In 2013, bioMérieux sales reached 1.588 billion euros, 87% of which were outside France. bioMérieux employs more than 8,500 employees worldwide.